Otsuka opts for majority JV as it links with Claris for IV products
This article was originally published in Scrip
Executive Summary
Following negotiations reported by Scrip earlier this week (scripintelligence.com, 4 December 2012), Otsuka Holdings has now announced a definitive agreement with India's Claris Lifesciences for a business tie-up in the area of intravenous solutions and clinical nutrition products.
You may also be interested in...
Fosun Pitches for India's Gland
Shanghai Fosun Pharmaceutical Group Co. Ltd. has confirmed it interest in the Indian injectables firm, Gland Pharma Ltd., underscoring how differentiated niche plays continue to attract buyer interest.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.